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Abstract
Background: Osteoporosis-related fractures are a significant public health concern. Interventions that increase
detection and treatment of osteoporosis are underutilized. This pragmatic randomised study was done to evaluate
the impact of a multifaceted community-based care program aimed at optimizing evidence-based management in
patients at risk for osteoporosis and fractures.
Methods: This was a 12-month randomized trial performed in Ontario, Canada. Eligible patients were community-
dwelling, aged ≥55 years, and identified to be at risk for osteoporosis-related fractures. Two hundred and one
patients were allocated to the intervention group or to usual care. Components of the intervention were directed
towards primary care physicians and patients and included facilitated bone mineral density testing, patient
education and patient-specific recommendations for osteoporosis treatment. The primary outcome was the
implementation of appropriate osteoporosis management.
Results: 101 patients were allocated to intervention and 100 to control. Mean age of participants was 71.9 ± 7.2
years and 94% were women. Pharmacological treatment (alendronate, risedronate, or raloxifene) for osteoporosis
was increased by 29% compared to usual care (56% [29/52] vs. 27% [16/60]; relative risk [RR] 2.09, 95% confidence
interval [CI] 1.29 to 3.40). More individuals in the intervention group were taking calcium (54% [54/101] vs. 20%
[20/100]; RR 2.67, 95% CI 1.74 to 4.12) and vitamin D (33% [33/101] vs. 20% [20/100]; RR 1.63, 95% CI 1.01 to 2.65).
Conclusions: A multi-faceted community-based intervention improved management of osteoporosis in high risk
patients compared with usual care.
Trial Registration: This trial has been registered with clinicaltrials.gov (ID: NCT00465387)
Background
Osteoporosis, a chronic condition characterized by low
bone mass, microarchitectural deterioration of bone and
increased risk of fracture, is a significant public health
concern. It affects over 200 million people worldwide [1],
an estimated 10 million people in the US [2], 4 million
people in the UK [3] and 1.4 million people in Canada
[2,4]. Fragility fractures are the clinical consequence of
osteoporosis. While vertebral fractures can cause back
pain, loss of height and disability [5-7], hip fractures have
a more significant impact on quality of life leading to loss
of function, and admission to long-term care [8-12]. It is
estimated that 1 in 5 people who suffer a hip fracture will
die during the first year and less than one third gain their
pre-fracture level of function [2]. Moreover, the eco-
nomic impact of this condition is considerable, with the
total acute care cost of osteoporosis estimated to be over
$1.3 billion per year in Canada [12], $20 billion in the US
[13] and over €30 billion in Europe [14,15]. Given that
the proportion of people aged 65 and older is increasing,
this will likely lead to an even more significant burden of
disease [4,15].
A substantial body of evidence supports the use of
various interventions for the detection and treatment
of osteoporosis in high risk patients, and the prevention
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min D, and drugs that decrease bone resorption or
increase bone formation [16]. For example, bisphospho-
nates reduce the risk of future osteoporosis-related frac-
ture by 40 to 60% with fracture reduction apparent
within a year of starting treatment [16].
Despite the incorporation of this evidence from rando-
mized trials into clinical practice guidelines, these inter-
ventions are considerably underutilized [17-23].
A systematic review found that the proportion of indivi-
duals with a fragility fracture who received a diagnostic
test for osteoporosis or a diagnosis from a physician
ranged from 1.7% to 50% [18]. Furthermore, rates of
osteoporosis treatment among elderly patients with a
fracture of the wrist, hip or vertebrae are less than 10 to
20% in the year following fracture [18].
These care gaps highlight the finding that additional
effort is needed to ensure that appropriate knowledge
translation is achieved to optimize management of
osteoporosis in patients at risk of fragility fractures. This
study was designed to help fill this knowledge to prac-
tice gap. The primary objective of this study was to
determine if a multicomponent, community-based strat-
egy could optimize the evidence-based management of
people at risk for osteoporosis-related fractures.
Methods
Between March 2003 and January 2006, we conducted a
randomized trial of a multifaceted community based
intervention to optimize care of patients at risk for
osteoporosis-related fractures. The complete study pro-
tocol has been published [24].
Setting and Study Population
This was a population-based study completed in the
Algoma District of Ontario, Canada, a geographically
vast area with Sault Ste Marie (population 78 000) as its
main city. The study represented a partnership among
consumers, providers and other stakeholders interested
i nr e d u c i n gt h ee v i d e n c et op r a c t i c eg a p .I tw a s
conducted by the Group Health Centre (GHC), a not-
for-profit health service community centre, in partner-
ship with Sault Area Hospital (SAH), a facility with 250
active beds.
Patients were eligible for inclusion in the study if they
were community-dwelling, aged 55 years or older, able
to give informed consent, and were identified to be at
risk for future fracture according to one of the following
criteria:
1. attended the hospital Fracture Clinic for a non-
pathological fracture of the vertebrae, hip or wrist or
had a BMD in the past year with a T-score of ≤-2.0
2. attended the hospital Emergency Department with
a fall and found to be at high risk for falls as defined
by a Timed Up and Go [25] result of greater than
14 seconds; or,
3. were self-referred or referred by a health care pro-
vider because of perceived high risk of fracture and
identified as a high risk for falls defined by a Timed
Up and Go result of greater than 14 seconds.
Patients already receiving appropriate pharmacological
therapy for osteoporosis as outlined in the Osteoporosis
Canada guidelines [16] were excluded from the study.
Intervention
The intervention was multifaceted and consisted of pro-
viding evidence-based management strategies for osteo-
porosis to both the patients and their primary care
providers. Following randomization, a bone mineral
density (BMD) test was facilitated for participants dur-
ing the intervention if it had not been done within the
past year, and the results were sent to the primary care
physician along with relevant prescribing information
based on the Osteoporosis Canada guidelines [16].
A complete list of the patient’s medications was com-
piled from two sources and provided to physicians: (1)
the patient’s pharmacy records; and (2) home visits con-
ducted by the study nurses. Medications associated with
increased risk of fracture were identified, and physicians
were asked to assess this list of flagged medications
(Appendix). The nurse assessed participants allocated to
the intervention group in their home and completed the
Berg Balance Scale [26], the InterRAI Screener [27,28],
a medication review and an assessment for orthostatic
hypotension
Patients received personalized counseling from the
research nurse about osteoporosis, including a written
summary of the proposed management plan. They also
received educational materials on calcium and vitamin
D, risk factors for osteoporosis, and their BMD results.
For those few individuals without a primary care physi-
cian, the same materials were provided but patients
were encouraged to visit a walk-in clinic or the emer-
gency department.
Allocation and Blinding
Eligible patients were randomized using a computer
generated randomization scheme under supervision of
the study biostatistician, into an immediate intervention
protocol (IP) group or to usual care. 6 months after ran-
domization participants in the usual care group received
the intervention and were thus described as the delayed
intervention protocol (DP) group. Patients, treating phy-
sicians and outcomes assessors could not be blinded to
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sis improvement study. All patients were followed-up at
6 and 12 months after the completion of the initial
assessment.
Outcomes and Data Collection
The primary outcome under investigation was appropri-
ate osteoporosis management based on the 2002 clinical
practice guidelines for osteoporosis in Canada [16]. This
was the most current evidence-based guideline available
for use at the time of study onset and was generally
consistent with current US and UK guidelines. Measure-
ments of outcomes were obtained through patient
records (obtained through the Electronic Medical
Record) and pharmacy data. A standardized chart review
of the Electronic Medical Record was the primary
source of data for both groups.
Secondary outcomes included appropriate osteoporosis
management at 12 months and disease-specific quality
of life measured using the OPTQoL [29], a quality of
life questionnaire for people with osteoporosis.
Sample size and Analysis
L o c a lp i l o td a t as u g g e s t e dt h a t4 0 %o fp e o p l ew o u l d
receive appropriate osteoporosis medications at
6 months. We determined a minimal clinically impor-
tant difference of 20% and with a two-tailed alpha of
0.05, power of 0.80, the patient as the unit of allocation
and analysis, and assuming a loss to follow-up of 10%, a
total sample size of 200 patients was needed.
Relative risks with 95% confidence intervals were cal-
culated to assess outcomes between the IP group and
the usual care group at 6 months. Fisher’sE x a c tT e s t
was used to evaluate differences in outcomes between
the IP group and the DP group at 12 months. Paired
t-tests were used to detect differences in the OPTQoL
at baseline and 6 months within each group. Analysis
was by intention to treat.
Ethics approval was received from the Joint Group
Health Centre/Sault Area Hospital Research and Ethics




590 patients were screened for eligibility, 389 were
excluded and 201 patients were recruited from March
2003 to January 2006, with 101 patients randomized
into the IP group, and 100 patients into the usual care
group (Figure 1). One hundred seventy six patients
(88%) completed the study. Mean age of participants
was 71.9 ± 7.2 years and 94% were women. Most parti-
cipants entered the study on the basis of a previous
BMD test or referral from fracture clinic suggesting that
the study population was at high risk of osteoporosis-
related fracture. Baseline characteristics were similar
among the groups (Table 1). No statistically significant
baseline differences were detected between groups with
respect to presence of risk factors or differences in
losses due to death and follow-up.
Primary Outcomes
Osteoporosis risk management
For osteoporosis risk management (Table 2), more than
twice the number of patients with osteoporosis (BMD
T-score ≤ -2.5) were taking alendronate, risedronate, or
raloxifene in the IP group after 6 months compared to
the usual care group (29/52 vs. 16/60; relative risk [RR]
2.09, 95% confidence interval (CI) 1.29 to 3.40). The dif-
ference in treatment rates was even greater for patients
with low bone mass (T-score between -2.5 and -1.0)
between the IP and usual care groups (16/39 vs. 5/31;
RR 2.54, 95% CI 1.05 to 6.17). A higher proportion of
patients in the IP group were using calcium (54/101 vs.
20/100; RR 2.67, 95% CI 1.74 to 4.12) and vitamin D
(33/101 vs. 20/100; RR 1.63, 95% CI 1.01 to 2.65) at
6 months compared to the usual care group. There
were more women in the IP group taking estrogen/
progestin compared to the usual care group at 6 months
(13/101 vs. 2/100; RR 6.77, 95% CI 1.49 to 27.8).
Secondary Outcomes
Osteoporosis management
Following intervention in both groups at 12 months
after randomization, the use of appropriate treatments
for osteoporosis (alendronate, risedronate, raloxifene
with BMD T-score ≤ -2.5) reached 56%. The usual care
g r o u pi m p r o v e dt ot h es a m el e v e lo ft r e a t m e n tw i t h
alendronate, risedronate, raloxifene, calcium, and vita-
min D after receiving the intervention (P=0.48)
(Table 2).
Quality of life and other patient-centered outcomes
Quality of life measured by the OPTQoL questionnaire
remained similar within the IP group (P = 0.58) and DP
group (P=0.26) over the course of the study (Table 2).
One participant in the IP group had a fragility fracture
at 6 months compared with 6 participants in the usual
care group (RR 0.17, 95% CI 0.02,1.35). Two individuals
in the IP group were admitted to hospital with a fall-
related injury compared with 3 in the usual care group
(RR 0.66, 95% CI 0.11 to 3.87).
Discussion
This study demonstrated that a multi-component inter-
vention program directed at patients at risk for fracture
and at their physicians doubled the rate of appropriate
osteoporosis management compared to usual care in
this community. The co-ordinated intervention
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than 20% over usual care, a consensus benchmark pre-
viously reported as what might be considered a clinically
important benefit for such an intervention [30]. Our
study increased pharmacological treatment of osteoporo-
sis by 29% over local usual care (IP 56% vs. DP 27%).
Similarly, a controlled trial by Majumdar et al reported
appropriate use of osteoporosis medications to be 40% in
the intervention group versus 10% in the usual care con-
trol, but only patients with a wrist fracture were eligible
for inclusion [31]. A more recent trial of a case manager
for patients with hip fracture found similar results to
what was observed in our study [32]. With the improve-
ments in care delivery observed in the current study, the
appropriate osteoporosis treatments were utilized in over
one-half of individuals with receipt of the intervention.
This result is better than that achieved in most other stu-
dies of interventions to enhance implementation of
osteoporosis management in broad populations of at-risk
patients rather than restricted to patients with recent
fracture. Randomized intervention studies directed at
physicians and/or patients at high risk of osteoporosis-
Figure 1 Flow of Trial Participants.







Mean age (years) ± SD 72 ± 9.1 71 ± 7.7
Female 92 (91.1%) 96 (96.0%)
Male 9 (8.90%) 3 (3.00%)
Aboriginal Origin 2 (1.98%) 9 (9.00%)
Referral Source, n (%)
#1 SAH Fracture Clinic or BMD t-score ≤-2.0 74 (72.6%) 73 (73.0%)
#2 SAH Emergency Department 4 (3.96%) 5 (5.00%)
#3 Self-referred or referred
by health care provider
and Timed Up and Go
(TUG) >14 s
23 (22.8%) 22 (22.0%)
Osteoporosis Risk Factors, n (%)*
T-score +2.5 to -1.0 10 (9.90%) 9 (9.00%)
T-score -1.0 to -2.5 39 (38.6%) 31 (31.0%)
T-score ≤ -2.5 52 (51.5%) 60 (60.0%)
Note: All participants had a BMD completed as per protocol.
*No significant differences were detected between groups
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[33,34] and by Elston Lafata and colleagues [35] found
that screening and treatment rates were either unaffected
[33,34] or improved by less than 10% [35]. And a recent
study of a falls-and-fracture nurse coordinator found that
neither falls nor osteoporosis management were
enhanced with this intervention [36]. Thus, the present
study achieved an effect size substantially larger than
recent studies of similar design.
The strengths of this study included a randomized
study design; an intervention targeted at high-risk
patients; the successful partnership between numerous
distinct community stakeholders; and that we were able
to ‘replicate’ the intervention’s effects 6 months later in
the DP group. Moreover, multiple health care providers
and community health service groups collaborated in a
coordinated assessment and treatment program to deli-
ver evidence-based and timely interventions. Economic
analysis of this study is currently underway.
The limitations of this study included: a short follow-up
period of 6 months, which did not allow for longer-term
results such as fracture data; and, no blinded outcomes
assessors. The lack of blinding of the outcomes assessors
could result in bias such as overestimation of the impact
of the intervention. However, the primary source of data
collection was the administrative data obtained from the
Group Health Centre Electronic Medical Record. Even if
we consider the lower limit of the confidence interval (for
use of appropriate pharmacological therapy [RR] 2.09, 95%
CI 1.29 to 3.40) as the effect size, we consider this a clini-
cally important change. Given that there is evidence that
appropriate management of osteoporosis decreases frac-
tures, it was felt that the use of appropriate management
as the primary outcome was relevant. Indeed, when the
evidence-base is well-established (such as in osteoporosis
management), process-of-care measures are more sensitive
to changes in quality of care than outcomes such as mor-
tality or clinical events and are widely recognized as accep-
table and appropriate endpoints for quality improvement
studies.
Conclusions
In summary, it is critical that the health care community
address the deficiencies that exist with respect to knowl-
edge translation and management of osteoporosis given
the significant burden of disease related to fractures. This
randomized, community-based study supports imple-
mentation of a co-ordinated osteoporosis management
strategy for improved care in at-risk individuals, although
long-term follow-up should be considered. Many of the
assessment and treatment protocols used in this study
could be employed in existing clinics and programs to
enhance osteoporosis care in a community setting.
Appendix: Risk Medications
Medications associated with an increased risk of osteo-
porosis:
1. Glucocorticoids: Cortef, cortisone, dexamethasone,
hydrocortisone, prednisone, betamethasone, fludro-
cortisone, methylprednisone, prednisolone,
tramcinolone.
2. Inhaled Corticosteroids: beclomethasone, budeso-
nide, fluticasone, flunisolide, tramcinolone.
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